Abstract
Background:Duration of untreated psychosis (DUP) is an important predictor of outcome in first-episode psychosis (FEP). Cannabis use is highly prevalent in FEP patients and it is important to evaluate the potential impact of cannabis use on DUP.
Methods: A systematic review of the literature was conducted to identify articles reporting DUP in FEP cannabis users (CU+) and nonusers (CU-) respectively. Studies meeting inclusion criteria were entered into a meta-analysis. In addition, a comparative review was conducted of the relationship between substance use and DUP.
Results: Nine studies were identified reporting DUP in CU+ versus CU- patients. Of the pooled sample of 1726 FEP patients, 39% were cannabis users. Although in most studies DUP was shorter in cannabis using patients, meta-analysis did not detect a significant relationship between DUP and cannabis use. A trend towards shorter DUP in substance users was also apparent in the comparative review; although in none of the studies did this association reach statistical significance.
Discussion: This review and meta-analysis suggests a trend association between shorter DUP and cannabis use in FEP; especially when cannabis use is defined in terms of current or recent use (rather than lifetime use.) Further research should aim to clarify the relative effects of longstanding versus recent onset cannabis use on neurobiology, pathway to care and outcome in FEP.
Keywords: First-episode psychosis (FEP), cannabis, duration of untreated psychosis (DUP), systematic review, meta-analysis, pathway to care
Current Pharmaceutical Design
Title:Cannabis use and Duration of Untreated Psychosis: A Systematic Review and Meta-Analysis
Volume: 18 Issue: 32
Author(s): Jonathan K. Burns
Affiliation:
Keywords: First-episode psychosis (FEP), cannabis, duration of untreated psychosis (DUP), systematic review, meta-analysis, pathway to care
Abstract: Background:Duration of untreated psychosis (DUP) is an important predictor of outcome in first-episode psychosis (FEP). Cannabis use is highly prevalent in FEP patients and it is important to evaluate the potential impact of cannabis use on DUP.
Methods: A systematic review of the literature was conducted to identify articles reporting DUP in FEP cannabis users (CU+) and nonusers (CU-) respectively. Studies meeting inclusion criteria were entered into a meta-analysis. In addition, a comparative review was conducted of the relationship between substance use and DUP.
Results: Nine studies were identified reporting DUP in CU+ versus CU- patients. Of the pooled sample of 1726 FEP patients, 39% were cannabis users. Although in most studies DUP was shorter in cannabis using patients, meta-analysis did not detect a significant relationship between DUP and cannabis use. A trend towards shorter DUP in substance users was also apparent in the comparative review; although in none of the studies did this association reach statistical significance.
Discussion: This review and meta-analysis suggests a trend association between shorter DUP and cannabis use in FEP; especially when cannabis use is defined in terms of current or recent use (rather than lifetime use.) Further research should aim to clarify the relative effects of longstanding versus recent onset cannabis use on neurobiology, pathway to care and outcome in FEP.
Export Options
About this article
Cite this article as:
K. Burns Jonathan, Cannabis use and Duration of Untreated Psychosis: A Systematic Review and Meta-Analysis, Current Pharmaceutical Design 2012; 18 (32) . https://dx.doi.org/10.2174/138161212802884672
DOI https://dx.doi.org/10.2174/138161212802884672 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Risk Analysis of Lurasidone in Patients with Schizophrenia and Bipolar Depression
CNS & Neurological Disorders - Drug Targets Impaired DNA Damage Repair as a Common Feature of Neurodegenerative Diseases and Psychiatric Disorders
Current Molecular Medicine <i>LncRNA</i> Xist, X-chromosome Instability and Alzheimer’s Disease
Current Alzheimer Research Practical Aspects in the Use of Biomarkers for the Development of Cancer Vaccines
Current Cancer Therapy Reviews Biological Relevance of Lysophospholipids and Green Solutions for Their Synthesis
Current Organic Chemistry A Validated Chiral Liquid Chromatographic Method for the Enantiomeric Separation of Orphenadrine Citrate in Pharmaceutical Dosage Form
Current Pharmaceutical Analysis Treatment of Internet Addiction in Patient with Panic Disorder and Obsessive Compulsive Disorder: A Case Report
CNS & Neurological Disorders - Drug Targets Treating COPD in Older and Oldest Old Patients
Current Pharmaceutical Design Subject Index to Volume 4
Current Topics in Medicinal Chemistry Central Nervous System Depressants and Risk of Hospitalization due to Community-Acquired Pneumonia in very Old Patients
Current Drug Safety Screening for Inhibitors of Microglia to Reduce Neuroinflammation
CNS & Neurological Disorders - Drug Targets Current Trends and Future Strategies for the Global Impact of COVID-19 Pandemic
Coronaviruses Approaching the Increasing Complexity of Non-small Cell Lung Cancer Taxonomy
Current Pharmaceutical Design Brain Derived Neurotrophic Factor and Cognitive Status: The Delicate Balance Among People Living with HIV, with and without Alcohol Abuse
Current HIV Research Molecular Aspects of the RT/drug Interactions. Perspective of Dual Inhibitors
Current Pharmaceutical Design Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?
Current Medicinal Chemistry Mechanisms for Radioprotection by Melatonin; Can it be Used as a Radiation Countermeasure?
Current Molecular Pharmacology Glutamate Transporter 1: Target for the Treatment of Alcohol Dependence
Current Medicinal Chemistry Regression to the Mean: Implications for Clinical Trials of Psychotropic Agents in Dementia
Current Alzheimer Research Manoglanistara - Emotional Wellness Phases Prediction of Adolescent Female Students by using Brain Waves
Current Signal Transduction Therapy